Eliza Vakana

Critical roles for mTORC2- and rapamycin-insensitive mTORC1-complexes in growth and survival of BCR-ABL-expressing leukemic cells

Nathalie Carayol, Eliza Vakana, Antonella Sassano et al. · Proceedings of the National Academy of Sciences · 2010 · 178 citations · Full text

Life Sciences, Oncology, Pharmacology +15

Autophagic degradation of the BCR-ABL oncoprotein and generation of antileukemic responses by arsenic trioxide

Dennis J. Goussetis, Elias Gounaris, Edward J. Wu et al. · Blood · 2012 · 130 citations · Full text

Life Sciences, Biochemistry, Cell Biology +16

Inhibition of Mnk kinase activity by cercosporamide and suppressive effects on acute myeloid leukemia precursors

Jessica K. Altman, Amy Szilard, Bruce W. Konicek et al. · Blood · 2013 · 99 citations · Full text

Medicine, Cancer Biology, Oncology +11

Antileukemic effects of AMPK activators on BCR-ABL–expressing cells

Eliza Vakana, Jessica K. Altman, Heather Glaser et al. · Blood · 2011 · 88 citations

Life Sciences, Cell Biology, Oncology +10

LY3009120, a panRAF inhibitor, has significant anti-tumor activity in BRAF and KRAS mutant preclinical models of colorectal cancer

Eliza Vakana, Susan E. Pratt, Wayne Blosser et al. · Oncotarget · 2016 · 69 citations · Full text

Medicine, Oncology, Pharmacology +17